Biomedica Life Sciences S.A. is a privately held, vertically integrated Specialty Pharmaceutical Company, headquartered in Greece (Athens), focused on the emerging field of Nuclear Medicine and more specifically in the Molecular Imaging and Targeted Therapies. The Company since its establishment in 1987 is dynamically active in the Health Sector and has established a leading position in covering the market needs of the health industry in diagnostic and therapeutic products, specific medical devices and services. Biomedica Life Sciences S.A. has launched and marketed a unique portfolio of innovative radiopharmaceutical products in Greece.
Technologies / Services offered or sought
The Company's core activity, utilising the expertise that has been developed through the past years, spans over the following fields:
Development and commercialisation of innovative products and services through internal R&D efforts
Sourcing late stage diagnostics and therapeutic products for development and commercialization internationally
Investing in research partnerships with academic institutions and research centres
BioMedica Life Sciences shows great interest in the research and development of novel products in a variety of fields such as the molecular diagnostic imaging and molecular therapy via radiolabeled biomolecules, the development of substances for pharmaceutical and cosmetic use and the peptide chemistry
The research efforts of BioMedica Life Sciences mainly focus on Molecular Radiopharmacology and expand in Nuclear Medicine. Nuclear medicine is a specialty that uses radionuclides and relies on the process of radioactive decay for the diagnosis and/or treatment of a disease. When radionuclides are bound to certain chemical compounds or biomolecules they form Radiopharmaceuticals which are the main tool for Nuclear Medicine. Radiopharmaceuticals once administered to the patient, can localise to specific organs or cellular receptors and allow the diagnosis or treatment of a disease based on the cellular function and physiology rather than relying on the anatomy.
Technology and R&D
BioMedica Life Sciences shows great interest in the research and development of novel products in a variety of fields such as the molecular diagnostic imaging and molecular therapy via radiolabeled biomelecules, the development of substances for pharmaceutical and cosmetic use and the peptide chemistry. The result of those efforts is that there is already one compound in a clinical evaluation stage and two pharmaceutical products (both “orphan drug” designated) which are entering Phase II and Phase III clinical trials.
- Radiolabeled biomolecules for molecular diagnosis & therapy
Retinoids for pharmaceutical & cosmetic application